You can call MIRG.org toll-free at (1-888-802-6376)

Current Mesothelioma Clinical Trials

Below are some of the most current mesothelioma clinical trials currently recruting patients. Before participating in a clinical trial, it is important that you learn all of the potential risks and benefits involved. You should consult with your doctor to determine if the trial is right for you.

—Columbia Center for Lung Failure and Mesothelioma Center Beginning a New Clinical Trial for Malignant Pleural Mesothelioma

The multidisciplinary, interdepartmental Center for Lung Failure and the Columbia University Mesothelioma Center are seeking patients for a new institutionally approved clinical protocol to treat malignant pleural mesothelioma, a rare tumor that attacks the pleura, the lining membrane of the lung. Mesothelioma occurs mainly in men over the age of 50 and is frequently associated with prior environmental or occupational exposure to asbestos. It can be diagnosed only by biopsy. Treatment often requires major surgery on the pleura and lung and may involve post-surgical chemotherapy and radiation treatment.. Learn more>>

—ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen

Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether Onconase plus doxorubicin is more effective than doxorubicin alone in treating patients with malignant mesothelioma. Learn more>>

—PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma

PTK787/ZK 222584 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Phase II trial to study the effectiveness of PTK787/ZK 222584 in treating patients with unresectable malignant mesothelioma. Learn more>>

—ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients with Malignant Pleural or Peritoneal Mesothelioma - Lung Cancer

This clinical trial is for people who have advanced malignant pleural or peritoneal mesothelioma. The purpose of this trial is to see if the study drugs, alimta and gemcitabine, have any effect on your cancer.Learn more>>

—FDA Approves Alimta-Cisplatin Combination for Treatment of Asbestos-Related Cancer

Alimta® ("uh-LIMB-ta"), to be introduced shortly by Eli Lilly and Company (NYSE: LLY), was approved for use with cisplatin, a standard chemotherapy agent, for the treatment of malignant pleural mesothelioma, a cancer of the lining of the lungs, in patients who are not candidates for surgery. Learn more>>

—Experimental Drug SS1(dsFv)-PE38 to Treat Cancer (Updated)

This study will determine the dose of the experimental anticancer drug SS1(dsFv)-PE38 that can be given safely to patients. It will also look at how the body handles the drug, its side effects, and its effect on the tumor. Learn more>>

—Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma

Phase II trial to study the effectiveness of combining photodynamic therapy with surgery in treating patients who have malignant mesothelioma. Learn more>>

—Phase I Study of Intrapleural BG00001 in Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions

Phase I trial to study the effectiveness of intrapleural BG00001 in treating patients who have malignant pleural mesothelioma or malignant pleural effusions.Learn more>>

—Phase I Study of SS1(dsFv)-PE38 Immunotoxin in Patients With Advanced Mesothelin-Expressing Malignancies

Phase I trial to study the effect on the body of immunotoxin therapy in treating patients who have recurrent, unresectable advanced solid tumors.Learn more>>

—Phase II Study of Alanosine in Patients With Methylthioadenosine Phosphorylase (MTAP)-Deficient Cancer

Phase II trial to study the effectiveness of alanosine in treating patients who have soft tissue sarcoma, sarcoma of the bone, mesothelioma, non-small cell lung cancer, or pancreatic cancer. Learn more>>

—Trial of Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer in Previously Treated Patients

Patients will be treated with oral Tarceva daily for 21 days each cycle. Patients will receive Avastin by IV on day 1 of each 21-day cycle. If a patient has no grade 3 or 4 toxicities after the 1st cycle, then the patient may continue the same doses of Tarceva and Avastin for another cycle. If the patient has response or stable disease after 6 weeks (2 cycles), the patient may continue on the same doses of Tarceva and Avastin. A patient may receive treatment on this study for up to one year, unless his or her disease progresses or side effects become too severe. Learn more>>

—Combination chemotherapy with or without bevacuzumab in treating patients with advanced, metastatic, or recurrent non-small cell lung cancer

Randomized phase II/III trial to study the effectiveness of combination chemotherapy with or without bevacizumab in treating patients who have advanced, metastatic, or recurrent non-small cell lung cancer. Learn more>>

—Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

Phase II trial to study the effectiveness of bevacizumab, paclitaxel, and carboplatin given before surgery in treating patients who have stage IB, stage II, or stage IIIA non-small cell lung cancer. Learn more>>